Module

Recent and Future Directions of Hormonal Therapy in Prostate Cancer

Source: Prostate Cancer Annual Update 2006

Recent and Future Directions of Hormonal Therapy in Prostate Cancer

Program Director: E. David Crawford, MD

Faculty:
Robert S. DiPaola, MD

CME CREDIT INFORMATION

Release Date: 03/22/06

Expiration Date: 03/21/07

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the strengths and limitations of studies on the use of androgen-deprivation therapy (ADT) in early-stage prostate cancer
Explain the implications of ongoing and pending national trials that will define the use of ADT in combination with chemotherapy
Review the rationale behind the use of ADT combined with targeted drugs or vaccine therapies in future studies

Topics covered include:

Introduction
Timing of Androgen Ablation Therapy
Androgen Deprivation Therapy and Radiation Therapy
Androgen Deprivation Therapy and Surgery
Antiandrogen Therapy in Localized Disease
Androgen Deprivation Therapy in Combination With Chemotherapy
Androgen Deprivation Therapy and Targeted Therapy
Summary—Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.